Updated interim results from the Phase IIa dose ranging study ALS-022335, simeprevir and odalasvir for the treatment of genotype 1 hepatitis C virus (HCV), were announced at the European Association for the Study of the Liver conference in September 2016. The study showed a sustained virologic response at 12 weeks post treatment (SVR12) or longer of 100% for all patients (n=60) who received three drugs. Moreover, one cohort (n=20) showed 100% SVR12 following only six weeks of treatment.
